531686 ADVIKLA

MPS Pharma Share Price

 

 

Start SIP in ADVIKLA

Start SIP

Performance

  • Low
  • ₹2
  • High
  • ₹2
  • 52 Week Low
  • ₹2
  • 52 Week High
  • ₹4
  • Open Price₹2
  • Previous Close₹2
  • Volume647

Investment Returns

  • Over 1 Month + 5.11%
  • Over 3 Month -7.04%
  • Over 6 Month -35.54%
  • Over 1 Year -56.88%

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -4
  • PEG Ratio
  • -4.5
  • Market Cap Cr
  • 4
  • P/B Ratio
  • 5.5
  • Average True Range
  • 0.09
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.28
  • RSI
  • 29.47
  • MFI
  • 34.13

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹1.85
+ 0.08 (4.52%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹2.06
  • 50 Day
  • ₹2.52
  • 100 Day
  • ₹2.70
  • 200 Day
  • ₹2.51

Resistance and Support

1.83 Pivot Speed
  • R3 1.94
  • R2 1.90
  • R1 1.87
  • S1 1.80
  • S2 1.76
  • S3 1.73

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-09-02 A.G.M.
2025-08-12 Quarterly Results
2025-05-28 Audited Results
2025-02-12 Quarterly Results

MPS Pharma F&O

MPS Pharma Shareholding Pattern

35.89%
37.11%
27%

About MPS Pharma

  • NSE Symbol
  • ADVIKLA
  • BSE Symbol
  • 531686
  • Managing Director
  • Mr. Peeyush Kumar Aggarwal
  • ISIN
  • INE537C01019

Similar Stocks to MPS Pharma

MPS Pharma FAQs

MPS Pharma share price is ₹1 As on 27 December, 2025 | 03:58

The Market Cap of MPS Pharma is ₹3.5 Cr As on 27 December, 2025 | 03:58

The P/E ratio of MPS Pharma is -4 As on 27 December, 2025 | 03:58

The PB ratio of MPS Pharma is 5.5 As on 27 December, 2025 | 03:58

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23